{"result": "(\"entity\"<|>CÁNCER<|>EVENT<|>Cáncer es una enfermedad caracterizada por el crecimiento descontrolado de células anormales en el cuerpo, con diferentes tipos asociados a factores de riesgo como la obesidad y el consumo de tabaco.)\n##\n(\"entity\"<|>NALTREXONA<|>ORGANIZATION<|>La naltrexona es un antagonista opiáceo utilizado en el tratamiento de la obesidad, bloqueando las endorfinas y ayudando a controlar el apetito.)\n##\n(\"entity\"<|>BUPROPION<|>ORGANIZATION<|>El bupropión es un medicamento utilizado como antidepresivo y en la deshabituación tabáquica, que actúa como un inhibidor de la recaptación de noradrenalina y dopamina.)\n##\n(\"entity\"<|>POMC<|>ORGANIZATION<|>POMC (proopiomelanocortina) es una hormona que juega un papel en la regulación del apetito y el gasto energético.)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prisión en Tiruzia donde se mantuvieron a los Aurelians como rehenes.)\n##\n(\"entity\"<|>CANCER PREVENTION-II<|>EVENT<|>El estudio Cancer Prevention-II investiga la relación entre la obesidad y la mortalidad por cáncer en hombres y mujeres en EE. UU.)\n##\n(\"relationship\"<|>NALTREXONA<|>BUPROPION<|>La naltrexona se utiliza en combinación con bupropión para tratar la obesidad, actuando sobre el sistema de control del apetito.<|>8)\n##\n(\"relationship\"<|>CÁNCER<|>CANCER PREVENTION-II<|>El estudio Cancer Prevention-II investiga la relación entre la obesidad y la mortalidad por cáncer, destacando la importancia de la obesidad como factor de riesgo.<|>7)\n##\n(\"relationship\"<|>BUPROPION<|>POMC<|>El bupropión actúa sobre las neuronas de la melanocortina (POMC), que son cruciales para la regulación del apetito.<|>6)\n##\n(\"relationship\"<|>CÁNCER<|>NALTREXONA<|>La naltrexona se menciona en el contexto de la obesidad, que es un factor de riesgo significativo para varios tipos de cáncer.<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: TRASTORNOS ELECTROLÍTICOS\n\n\n\n   En la tabla 2 se pueden apreciar los riesgos relativos de incremento de riesgo para dife-                                              COMENTARIO\n   rentes tipos de cáncer, según niveles de evidencia. Los mayores son para                                   endometrio y                La naltrexona es un conocido antagonista opiáceo; por tanto, su acción es bloquear las\n   carcinoma esofágico.                                                                                                                   endorfinas y no estimularlas. La naltrexona se emplea en el tratamiento de la obesidad en\n   El sobrepeso y la obesidad son los principales determinantes del cáncer tras el consumo de taba-                                       combinación con el bupropión, que se utiliza en la deshabituación tabáquica y como anti-\n   co. En EE. UU., un 14% de la mortalidad por cáncer en hombres y un 20% en mujeres son atribui-                                         depresivo. El bupropión es un inhibidor de la recaptación de noradrenalina y dopamina que\n   bles al exceso ponderal. En el estudio Cancer Prevention-II, los hombres con obesidad mórbida                                          ejerce una acción anorexígena, actuando sobre las neuronas de la melanocortina (POMC)\n   se asociaron con un 52% de mortalidad respecto a normopeso (mayor en páncreas [RR 2,61]y                                               que, a su vez, libera α-MSH que actúa en los receptores de melanocortina-4 (MC4-R). Esta\n   hepatocarcinoma [RR 4,52]). En las mujeres con obesidad mórbida, el cáncer se asoció con un 62%                                        acción tiene un mecanismo de feedback, mediado por una β-endorfina, que anula esta ac-\n   de mayor mortalidad; en concreto destaca el carcinoma renal (RR 4,75) y el de endometrio (RR 6,5).                                     ción anorexígena. Sin embargo, la asociación con naltrexona, al actuar como antagonista\n                                                                                                                                          de los receptores µ-opioides, permite que la actividad del bupropión se mantenga durante\n   Tabla 2. Riesgo relativo de incremento de riesgo para diferentes tipos de cáncer, según                                                largo tiempo.\n   niveles de evidencia                                                                                                                   Las otras respuestas (A, B y D) son correctas.\n     TIPO DE CÁNCER                     EVIDENCIA ALTA              TIPO DE CÁNCER                    EVIDENCIA MEDIA\n     Endometrio                                  3,5                Estómago                                    2,0                                                                                                                                Disminución del\n     Esófago                                     3,0                Vesícula biliar                             2,0                                                                                                                              apetito e incremento\n     Renal                                       2,5                Páncreas                                    1,7                                                                                                                              del gasto energético\n     Colorrectal                               1,5-2,0              Hígado                                    1,5-4,0\n     Mama (posmenopausia)                        1,5                Mieloma múltiple                          1,5-3,0                                                                                                             R-MC4\n                                                                                                                                                                                                       a-MSH\n     Ovario                                    1,0-1,5              Meningioma                                1,5-3,0\n     Tiroides                                  1,0-1,5                                                                                                                                                                                 Feedback inhibitorio\n                                                                                                                                                                                                                                       ß-endorfina sobre POMC\n   Valores promedios basados en Calle EE & Kaaks (Nat Rev Cancer. 2004) y Lauby-Secretan B, et al. (N Engl J Med. 2016).\n\n\n\n   Referencias:\n   • Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: Emerging biological mechanisms and perspectives.                                                                                    POMC                     Antagonista receptor\n     Metabolism. 2019;92:121-35.                                                                                                                                                     Estímulo                                                 opioide (naltrexona)\n   • Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:                                                     POMC\n     579-91.                                                                                                                                                                        Bupropión\n   • Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort                                                                      a-MSH      ß-endorfina\n     of U.S. adults. N Engl J Med. 2003;348:1625-38.\n   • Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et et al. Body fatness and cancer—viewpoint of the IARC\n     Working Group. N Engl J Med. 2016;375:794-8.\n\n\n\n8  Señale la respuesta falsa en relación con el tratamiento médico de la obesidad:                                                        Figura 6. Mecanismo de acción de bupropión-naltrexona.\n                                                                                                                                          α-MSH: hormona estimulante de melanocitos; POMC: proopiomelanoc\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}